The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Amarin | Spons ADR | 023111206 | 51,113 | 8,087,486 | SH | DFND | 8,087,486 | 0 | 0 | ||
Anthera | Common | 03674U102 | 1,756 | 437,995 | SH | DFND | 437,995 | 0 | 0 | ||
Cempra | Common | 15130J109 | 8,207 | 714,285 | SH | DFND | 714,285 | 0 | 0 | ||
GW Pharma | Spons ADR | 36197T103 | 1,737 | 102,200 | SH | DFND | 102,200 | 0 | 0 | ||
Hyperion | Common | 44915N101 | 1,631 | 62,500 | SH | DFND | 62,500 | 0 | 0 | ||
Oncogenex Pharma | Common | 68230A106 | 5,609 | 603,740 | SH | DFND | 603,740 | 0 | 0 | ||
Portola | Common | 737010108 | 33,195 | 1,240,917 | SH | DFND | 1 | 1,240,917 | 0 | 0 | |
Prosensa | Common | N71546100 | 41,012 | 6,213,924 | SH | DFND | 6,213,924 | 0 | 0 | ||
Supernus | Common | 868459108 | 26,352 | 3,600,000 | SH | DFND | 1 | 3,600,000 | 0 | 0 | |
Zalicus | Common | 98887C105 | 564 | 473,800 | SH | DFND | 473,800 | 0 | 0 | ||
Zogenix | Common | 98978L105 | 4,320 | 2,335,218 | SH | DFND | 1 | 2,335,218 | 0 | 0 |